ASCO Updates Guidelines on Bone-Modifying Drugs in Breast Cancer

Publication
Article
Oncology Nursing NewsApril 2011
Volume 5
Issue 2

ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.

The American Society of Clinical Oncology (ASCO) has developed a new set of recommendations for using bone-modifying agents for patients with metastatic breast cancer amid growing therapeutic options and fresh concerns about serious skeletal-related events.

The ASCO panel said only patients with evidence of bone metastases should be treated with the therapy, and that there is insufficient evidence to demonstrate greater efficacy of 1 bone-modifying agent over another.

The options are: denosumab 120 mg subcutaneously every 4 weeks; intravenous pamidronate 90 mg over no fewer than 2 hours; or zoledronic acid 4 mg over no fewer than 15 minutes every 3 to 4 weeks. Serum creatinine should be monitored before each dose, and patients should receive dental care before and during therapy.

(Full Story)

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Photo of a woman with brown hair and bangs, surrounded by a blue border
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame